On September 5, Dr. Martin Bonde, CEO of Vaccibody will visit BioInnovation Institute at the popular event series ‘Talks at the Square’ to give a talk on “Key Findings – attained from creating biotech start-ups over 25 years”
At the talk, you will hear about Dr. Martin Bonde’s journey as an entrepreneur, which barriers he has encountered along the way, and how he has tried to navigate around these barriers.
Date: September 5th 2019
Time: 13:30 – 15:45
Venue: BioInnovation Institute, Ole Maaløes Vej 3, 2200 Copenhagen
Martin Bonde is a serial entrepreneur and has been working with life science start-ups since the mid-90s. In 2015, he fronted the sales of Epitherapeutics to Gilead for DKK 444 mill. Today he is the CEO of Vaccibody and holds board member positions in Orphazyme A/S, Visiopharm A/S and BioInnovation Institute.
Program of the day
|
13:30 – 14:00 |
Doors open |
|
14:00 – 14:05 |
Welcome by Jens Nielsen, CEO BII |
|
14:05 – 14:40 |
Martin Bonde: Key Findings – attained from creating biotech start-ups over 25 years |
|
14:40 – 14:50 |
Fireside chat with Martin and Jens |
|
14:50 – 15:00 |
Q&A |
|
15:00 – 15:45 |
Networking and closing reception |
Please note, the event has free admittance with 100 tickets available. Please sign up quickly to secure your seat.
About Martin Bonde
Dr. Martin Bonde has more than 25 years of international experience from the biotech industry. He started his career in Dako A/S, and has held seven CEO positions and one EVP position, among others in Ostemeter A/S (CEO), Torsana Biosensor A/S (CEO), Celtor Biosystems Inc (EVP), Combio A/S (CEO) and most recently Epitherapeutics Aps now sold to Gilead (CEO). His experience includes a significant number of transactions within business development, trade sales, mergers & acquisitions as well as management of research and development. From 2012-18 he was the Chairman of the biotech organization DANSK BIOTEK.
Dr. Bonde holds a Ph.D. in Immunochemical Techniques and a Master of Science in Chemical Engineering from the Technical University of Denmark as well as a Graduate Diploma (HD) in International Economy from Copenhagen Business School.